Multicenter point prevalence evaluation of the utilization and safety of drug therapies for COVID-19 at the onset of the pandemic timeline in the United States

KEY POINTS: In a multicenter point-prevalence study, we found that the rate of supportive care was high; among those receiving COVID-19 drug therapies, adverse reactions occurred in 12% of patients. PURPOSE: There are currently no FDA-approved medications for the treatment of coronavirus disease 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Rhodes, Nathaniel J, Dairem, Atheer, Moore, William J, Shah, Anooj, Postelnick, Michael J, Badowski, Melissa E, Michienzi, Sarah M, Borkowski, Jaime L, Polisetty, Radhika S, Fong, Karen, Spivak, Emily S, Beardsley, James R, Hale, Cory M, Pallotta, Andrea M, Srinivas, Pavithra, Schulz, Lucas T
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929420/
https://www.ncbi.nlm.nih.gov/pubmed/33537767
http://dx.doi.org/10.1093/ajhp/zxaa426

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7929420/
https://www.ncbi.nlm.nih.gov/pubmed/33537767
http://dx.doi.org/10.1093/ajhp/zxaa426

Ejemplares similares